Literature DB >> 34605885

What the Aducanumab Approval Reveals About Alzheimer Disease Research.

Jennifer J Manly1, M Maria Glymour2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34605885     DOI： 10.1001/jamaneurol.2021.3404

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  9 in total

1.  Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Cohort Study.

Authors:  Consuelo H Wilkins; Charles C Windon; Peggye Dilworth-Anderson; Justin Romanoff; Constantine Gatsonis; Lucy Hanna; Charles Apgar; Ilana F Gareen; Carl V Hill; Bruce E Hillner; Andrew March; Barry A Siegel; Rachel A Whitmer; Maria C Carrillo; Gil D Rabinovici
Journal:  JAMA Neurol       Date:  2022-10-03       Impact factor: 29.907

2.  Isolated REM sleep behavior disorder in North American older adults in an integrated health care system.

Authors:  Isabelle Havis; Trinity Coates; Kara J Wyant; C Chauncey Spears; Mark Garwood; Vikas Kotagal
Journal:  J Clin Sleep Med       Date:  2022-09-01       Impact factor: 4.324

3.  Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.

Authors:  Gregory S Day; Nikolaos Scarmeas; Richard Dubinsky; Katherine Coerver; Anitra Mostacero; Brooks West; Scott R Wessels; Melissa J Armstrong
Journal:  Neurology       Date:  2022-02-23       Impact factor: 11.800

Review 4.  A cultural approach to dementia - insights from US Latino and other minoritized groups.

Authors:  Clara Vila-Castelar; Joshua T Fox-Fuller; Edmarie Guzmán-Vélez; Dorothee Schoemaker; Yakeel T Quiroz
Journal:  Nat Rev Neurol       Date:  2022-03-08       Impact factor: 44.711

5.  A large pragmatic trial is the right solution for testing anti-amyloid therapies for Alzheimer's disease.

Authors:  M Maria Glymour; Vincent Mor
Journal:  J Am Geriatr Soc       Date:  2022-02-14       Impact factor: 7.538

6.  Effects of Tianeptine Treatment on Depression and Cognitive Function in Patients with Alzheimer's Disease: A 12-Month Retrospective Observational Study.

Authors:  José María García-Alberca; Esther Gris; Paz de la Guía; Silvia Mendoza
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

7.  Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society.

Authors:  Claire M Erickson; Lindsay R Clark; Fred B Ketchum; Nathaniel A Chin; Carey E Gleason; Emily A Largent
Journal:  Alzheimers Dement (Amst)       Date:  2022-08-25

8.  Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model.

Authors:  Wenrui Hao; Suzanne Lenhart; Jeffrey R Petrella
Journal:  PLoS Comput Biol       Date:  2022-09-02       Impact factor: 4.779

Review 9.  Moving Forward from the COVID-19 Pandemic: Needed Changes in Movement Disorders Care and Research.

Authors:  B Y Valdovinos; J S Modica; R B Schneider
Journal:  Curr Neurol Neurosci Rep       Date:  2022-02-02       Impact factor: 6.030
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.